Metabolic reprogramming: A key mechanism underlying chemotherapy resistance in non-small cell lung cancer

Chenchen Zhao; Tong Wu; Zhuting Li; Xianbin Kong

doi:10.36922/EJMO026030034

Eurasian Journal of Medicine and Oncology ›› 2026, Vol. 10 ›› Issue (3) :026030034 DOI: 10.36922/EJMO026030034

LETTER TO EDITOR

research-article

Metabolic reprogramming: A key mechanism underlying chemotherapy resistance in non-small cell lung cancer

Chenchen Zhao ¹^,^†
, Tong Wu ²^,^†
, Zhuting Li ¹^,^*
, Xianbin Kong ³^,^*

Author information +

History +

PDF (632KB)

Cite this article

Download citation ▾

Chenchen Zhao, Tong Wu, Zhuting Li, Xianbin Kong. Metabolic reprogramming: A key mechanism underlying chemotherapy resistance in non-small cell lung cancer. Eurasian Journal of Medicine and Oncology, 2026, 10 (3) : 026030034 DOI:10.36922/EJMO026030034

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Peixoto BP, Clague RA, Reddy JP, Wettersten HI. The emerging roles of metabolic reprogramming in non-small cell lung cancer progression. Front Biosci (Landmark Ed). 2025; 30(7):31363. doi: 10.31083/fbl31363

[2]	Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 2009; 324(5930):1029-1033. doi: 10.1126/science.1160809

[3]	Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004; 4(11):891-899. doi: 10.1038/nrc1478

[4]	Weinberg F, Hamanaka R, Wheaton WW, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A. 2010; 107(19):8788-8793. doi: 10.1073/pnas.1003428107

[5]	Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016; 23(1):27-47. doi: 10.1016/j.cmet.2015.12.006

[6]	Zhao C, Wu T, Kong X, Li Z. Application of natural killer cell-based immunotherapy in lung cancer treatment. Eurasian J Med Oncol. 2025; 9:35-48. doi: 10.36922/ejmo025110051

[7]	Sun X, Zhao P, Li H, Liu Y, Wang T, Cheng Y. Ginsenoside Rh2 inhibits glycolysis through the STAT3/c-MYC axis in non-small-cell lung cancer. J Oncol. 2021; 2021:9715154. doi: 10.1155/2021/9715154